DARA Biosciences Inc (NASDAQ:DARA), an oncology supportive care pharmaceutical company dedicated to providing health care professionals a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage side effects arising from their cancer treatment, announced the launch of a smartphone app to provide cancer patients an educational resource to help improve oral care and management of oral mucositis. This is being accompanied by the release of a list of “Top 10 Oral Care Tips” for Cancer Patients. DARA Biosciences Inc (NASDAQ:DARA), weekly performance is -28.75%. On last trading day company shares ended up $1.14. Analysts mean target price for the company is $2.00. DARA Biosciences Inc (NASDAQ:DARA), distance from 50-day simple moving average (SMA50) is -41.26%.
On May 29, 2014, During early morning , 22nd Century Group Inc (NYSEMKT:XXII), announced that its wholly-owned holding company, Goodrich Tobacco Company LLC, has entered into an agreement with Poland based Orion, which is also a cigarette manufacturer. The letter of intent exchanged between the two companies is with respect to 22nd Century’s plan to give Orion, a contract to manufacture and distribute its patented tobacco products across the European continent. 22nd Century Group Inc (NYSEMKT:XXII), fell 0.97% in last trading session and ended the day on $3.07. XXII, return on assets is -468.20%. 22nd Century Group Inc (NYSEMKT:XXII), quarterly performance is -27.76%.
Sigma-Aldrich Corporation (NASDAQ:SIAL), was named in the top five on Newsweek’s 2014 Green Rankings, one of the world’s foremost corporate environmental rankings. In its third appearance on the list, Sigma-Aldrich ranked number five out of 500 U.S. corporations, putting the St. Louis-based life science company in the top 1 percent for environmental performance.Sigma-Aldrich Corporation (NASDAQ:SIAL), shares moved up 0.94% in last trading session and was closed at $99.55, while trading in range of $98.02 – 99.68. Sigma-Aldrich Corporation (NASDAQ:SIAL), year to date (YTD) performance is 54.44%.
Corcept Therapeutics Incorporated (NASDAQ:CORT), Director G Leonard Baker, Jr. bought 100,000 shares of the company’s stock on the open market in a transaction dated Friday, May 9th. The shares were purchased at an average price of $1.84 per share, with a total value of $184,000.00. Following the completion of the purchase, the director now directly owns 578,389 shares of the company’s stock, valued at approximately $1,064,236. Corcept Therapeutics Incorporated (NASDAQ:CORT), ended the last trading day at $2.34. Company weekly volatility is calculated as 6.65% and price to cash ratio as 5.41. Corcept Therapeutics Incorporated (NASDAQ:CORT), showed a negative weekly performance of 4.00%.
Hyperion Therapeutics Inc (NASDAQ:HPTX), announced that the validation period is complete for its New Drug Submission (NDS) to Health Canada for RAVICTI (glycerol phenylbutyrate) Oral Liquid for the treatment of urea cycle disorders (UCDs), and that the RAVICTI NDS was granted Priority Review. Standard review in Canada takes 18 months or more and Priority Review, which is granted to promising medicines that address life-threatening or severely debilitating conditions, shortens the review time to approximately six months. Hyperion Therapeutics Inc (NASDAQ:HPTX), net profit margin is 44.20% and weekly performance is 4.98%. On last trading day company shares ended up $29.75. Analysts mean target price for the company is $39.20. Hyperion Therapeutics Inc (NASDAQ:HPTX), distance from 50-day simple moving average (SMA50) is 16.25%.
Leave a Reply